Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial

Summary: Background: The Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial found that biannual mass distribution of azithromycin to children younger than 5 years in Niger reduced the primary outcome of all-cause mortality by 18%. We aimed to determine the causes...

Full description

Bibliographic Details
Main Authors: Jeremy D Keenan, ProfMD, Ahmed M Arzika, MPH, Ramatou Maliki, MPH, Sanoussi Elh Adamou, MD, Fatima Ibrahim, RN, Mariama Kiemago, RN, Nana Fatima Galo, RN, Elodie Lebas, RN, Catherine Cook, MPH, Benjamin Vanderschelden, BSc, Robin L Bailey, ProfBM, Sheila K West, ProfPhD, Travis C Porco, ProfPhD, Thomas M Lietman, ProfMD, Paul M Emerson, Jerusha Weaver, Sheila K West, Robin L Bailey, John Hart, Amza Abdou, Boubacar Kadri, Nassirou Beido, E Kelly Callahan, Aisha E Stewart, Ahmed M Arzika, Sanoussi Elh Adamou, Nana Fatima Galo, Fatima Ibrahim, Salissou Kane, Mariama Kiemago, Ramatou Maliki, Catherine Cook, Sun Y Cotter, Thuy Doan, Dionna M Fry, Jeremy D Keenan, Elodie Lebas, Thomas M Lietman, Ying Lin, Kieran S O'Brien, Catherine E Oldenburg, Travis C Porco, Kathryn J Ray, Philip J Rosenthal, George W Rutherford, Benjamin Vanderschelden, Nicole E Varnado, Lina Zhong, Zhaoxia Zhou
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X19305406